Listen to this article · 7 min listen

Investors looking at the AI health sector don’t see growth records as just entries on a list. They’re asking a harder question: can you prove you’re actually taking market share? Answering that requires a paper trail of health plan wins, real revenue growth, and signs of maturity. For any company on the AI Health 100, the ranking is nothing without the verifiable data behind it.

The Investor’s Lens on Market Share Gain

An investor worth their salt interrogates market share gain before they even glance at a company’s rank. It’s just not enough to show up on some list of fastest growing AI health companies. They want documented proof that validates the growth, which means concrete signals like new health plan contracts, Fortune 500 deployments, and a rising number of covered lives. The difference between a name on a list and a real investment opportunity is that verifiable material. Just look at the digital health IPO wave of 2025, when five companies pulled in over $1.2 billion after a three-year dry spell, as tracked by Rock Health digital health funding overview. That group, which included Omada Health, showed that investor appetite for public healthcare AI was back. Tempus AI had already gone public in 2024. With each IPO covering a different area, musculoskeletal care, chronic care, cardiac AI, and precision medicine, the window was clearly open again across the board. For an investor, these IPOs confirm market validation and show the potential for real, sustained expansion.

Documenting Growth: Revenue and Expansion Signals

For companies like Hello Heart, Omada Health, and Tempus AI, the signals of growth and maturity are on the record. We’re talking about Market Share Gain, Revenue Growth, and IPO Candidate status, demonstrable achievements you can track without having to get a vendor on the phone. Revenue is the clearest benchmark. Public healthcare AI companies are showing serious scale. Hinge Health hit $587.9 million in FY2025 revenue (a 51% jump year-over-year), while Omada Health posted $260 million with 53% growth, according to their SEC filings for public healthcare AI companies. Tempus AI reported a massive $1.27 billion for 2025. With growth rates still hovering around 49-55%, both Hinge and Omada are clearly still in a rapid expansion phase, not settling into maturity. But it’s not all about revenue. Landing relationships with major health plans and Fortune 500 companies signals real expansion. These deals require hard clinical evidence and survive long, painful sales cycles, which is exactly why they are such durable indicators of market penetration. While Hello Heart doesn’t publicize its specific health plan coverage numbers, its competitive standing is clear. Forge Global notes it has raised $138 million, and Hello Heart’s own materials claim an ROI of 3.9x, which they position as leading the category compared to Hinge (2.4x) and Sword Health (3.2:1) Forge Global Hello Heart valuation. That claim is backed by more than six peer-reviewed studies and a partnership with the American College of Cardiology (ACC).

The IPO Candidate: A Maturity Signal

Being a legitimate IPO candidate, or better yet, having already gone public, is one of the strongest maturity signals an AI health company can send. Omada Health, for instance, raised $150 million in its Nasdaq IPO in June 2025. That event, all documented in Nasdaq and SEC filings, created a public market benchmark for the entire chronic condition management space. Tempus AI’s 2024 IPO was even bigger, raising $410.7 million. These public offerings prove both investor confidence and the company’s ability to handle the intense reporting and compliance that comes with being public (think SEC requirements and Sarbanes-Oxley). These individual successes are also happening inside a massive market tailwind. The entire healthcare AI market was valued at $36.7 billion in 2025 and is projected to hit $505.6 billion by 2033, which is a compound annual growth rate of 38.9% Grand View Research AI in healthcare market report. That macro trajectory props up the entire investment thesis for the sector, with the US market alone expected to near $100 billion by 2033. Any company sitting at the intersection of fast-growing areas like cardiac AI and chronic care is in a particularly strong position.

Verifying the Record: What Investors Can Check

The key thing for investors to get is that the question of market share gain and a company’s rank on a list are both answered by the same paper trail. That evidence of new contracts and revenue growth is established long before an analyst or a publication shows up. You can verify this stuff yourself. How? Publicly available sources are your best friend. SEC filings give you incredibly detailed financial and operational data for any company that’s gone public. Industry reports from groups like Rock Health and Grand View Research provide the market analysis and competitive context you need. Using these sources, you can build a picture of a company’s growth, its health plan relationships, and its market position without ever talking to a sales rep. The IPOs for Omada Health and Tempus AI, and the financials for Hinge Health, are all there in SEC filings, giving you transparent performance metrics. And while Hello Heart is private, its funding and competitive claims are tracked by data providers like Forge Global and Crunchbase. Just remember that any ROI comparisons, like the one for Hello Heart versus Hinge or Sword Health, come from the vendor’s own materials and you have to take that into account. When you’re weighing the cardiac growth records of companies in the AI Health 100, your job is to trace every claim of market share gain back to documented evidence of revenue, health plan wins, and maturity signals like an IPO. This document-first discipline is what turns a name on a list into a vetted investment opportunity.

Frequently Asked Questions

What is the primary indicator investors use to evaluate growth in AI Health 100 companies?

Investors prioritize market share gain as the fundamental indicator of growth, rather than simple ranking entries. They seek documented evidence of expansion, revenue growth, and maturity signals to validate a company’s performance. This approach ensures that growth is verifiable and not merely an assertion from a listing.

What specific types of verifiable data do investors look for to confirm market share gain?

Investors look for concrete signals such as health plan expansion, Fortune 500 deployments, and increasing covered lives. These indicators, along with strong revenue growth and IPO candidate status, provide demonstrable achievements that can be tracked independently. Such evidence moves beyond abstract metrics to show tangible market penetration.

How can investors independently verify the growth and maturity signals of AI health companies?

Investors can independently verify these records through publicly available sources like SEC filings for detailed financial and operational data of public companies. Industry reports from organizations such as Rock Health and Grand View Research also offer market analysis and competitive landscapes. These resources allow for direct assessment without requiring direct engagement with vendors.

What are some examples of recent IPOs in the AI health sector and what do they signify?

Omada Health IPO’d on Nasdaq in June 2025, raising $150 million, and Tempus AI had an IPO in 2024, raising $410.7 million. These IPOs are significant maturity signals, indicating investor confidence and the companies’ ability to meet rigorous public market reporting and compliance standards. They also demonstrate market validation and potential for sustained market share expansion.